Remodeling “cold” tumor immune microenvironment via epigenetic-based therapy using targeted liposomes with in situ formed albumin corona

Lactoferrin/Hyaluronic acid double-coated lignosulfonate nanoparticles of quinacrine as a controlled release biodegradable nanomedicine targeting pancreatic cancer

(2020) Samar M. Etman et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway

(2020) Xinjian Xu et al.   Frontiers in Microbiology

HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models

(2020) Trang Thi Thu Nguyen et al.   JOURNAL OF CLINICAL INVESTIGATION

Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy

(2020) Bin Tu et al.   Frontiers in Cell and Developmental Biology

Metabolic modulation via mTOR pathway and anti-angiogenesis remodels tumor microenvironment using PD-L1-targeting codelivery

(2020) Binfan Chen et al.   BIOMATERIALS

Nanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy

(2020) Yuefei Zhu et al.   Acta Pharmaceutica Sinica B

Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan/JQ1 for chemo-immunotherapy

(2020) Zhi-di He et al.   ACTA PHARMACOLOGICA SINICA

Immunotherapy in colorectal cancer: rationale, challenges and potential

(2019) Karuna Ganesh et al.   Nature Reviews Gastroenterology & Hepatology

Reprogramming Tumor Immune Microenvironment (TIME) and Metabolism via Biomimetic Targeting Codelivery of Shikonin/JQ1

(2019) Hairui Wang et al.   NANO LETTERS

Dual regulatory mechanisms of expression and mutation involving metabolism-related genes FDFT1 and UQCR5 during colorectal cancer liver metastasis

(2019) Yu-Shui Ma et al.   Molecular Therapy-Oncolytics

Tumor Angiogenic Inhibition Triggered Necrosis (TAITN) in Oral Cancer

(2019) Saori Yoshida et al.   Cells

Epithelial NOTCH Signaling Rewires the Tumor Microenvironment of Colorectal Cancer to Drive Poor-Prognosis Subtypes and Metastasis

(2019) Rene Jackstadt et al.   CANCER CELL

The emerging role of epigenetic therapeutics in immuno-oncology

(2019) Michael J. Topper et al.   Nature Reviews Clinical Oncology

Roles of Albumin-binding Proteins in Cancer Progression and Biomimetic Targeted Drug Delivery

(2018) Yongzhuo Huang et al.   CHEMBIOCHEM

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

(2018) Daniele V. F. Tauriello et al.   NATURE

Dual-targeting biomimetic delivery for anti-glioma activity via remodeling the tumor microenvironment and directing macrophage-mediated immunotherapy

(2018) Pengfei Zhao et al.   Chemical Science

Mathematical Modeling of the Function of Warburg Effect in Tumor Microenvironment

(2018) Milad Shamsi et al.   Scientific Reports

Trichostatin a Protects Dendritic Cells Against Oxygen-Glucose Deprivation via the SRSF3/PKM2/Glycolytic Pathway

(2018) Hongyun Jiang et al.   Frontiers in Pharmacology

BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response inKras-Mutant Non–Small Cell Lung Cancer

(2018) Dennis O. Adeegbe et al.   Cancer Immunology Research

Remodeling Tumor-Associated Macrophages and Neovascularization Overcomes EGFRT790M -Associated Drug Resistance by PD-L1 Nanobody-Mediated Codelivery

(2018) Weimin Yin et al.   Small

Metabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets

(2018) Vera Miranda-Gonçalves et al.   Frontiers in Genetics

Modulation of antitumor immunity with histone deacetylase inhibitors

(2017) Tyler R McCaw et al.   Immunotherapy

Histone Deacetylase Inhibitors as Anticancer Drugs

(2017) Tomas Eckschlager et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Protein corona: a new approach for nanomedicine design

(2017) Van Hong Nguyen et al.   International Journal of Nanomedicine

Reprogramming Tumor-Associated Macrophages To Reverse EGFRT790M Resistance by Dual-Targeting Codelivery of Gefitinib/Vorinostat

(2017) Huige Peng et al.   NANO LETTERS

Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages

(2017) Jennifer L. Guerriero et al.   NATURE

Neutrophils and Snail Orchestrate the Establishment of a Pro-tumor Microenvironment in Lung Cancer

(2017) Julien Faget et al.   Cell Reports

BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1

(2017) Simon J. Hogg et al.   Cell Reports

Histone Deacetylase Inhibitors in Tumor Immunotherapy

(2017) Li-Ming Zhao et al.   CURRENT MEDICINAL CHEMISTRY

Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer

(2016) Hanlin Zeng et al.   CANCER CELL

Attenuation of the programmed cell death-1 pathway increases the M1 polarization of macrophages induced by zymosan

(2016) W Chen et al.   Cell Death & Disease

BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression

(2016) Hengrui Zhu et al.   Cell Reports

Liposome–protein corona in a physiological environment: Challenges and opportunities for targeted delivery of nanomedicines

(2015) Giulio Caracciolo   Nanomedicine-Nanotechnology Biology and Medicine

Lactic acid polarizes macrophages to a tumor-promoting state

(2015) Oscar R Colegio   OncoImmunology

Tumor-Associated Macrophages: From Mechanisms to Therapy

(2014) Roy Noy et al.   IMMUNITY

The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity

(2013) David M. Woods et al.   MELANOMA RESEARCH

Fueling Immunity: Insights into Metabolism and Lymphocyte Function

(2013) E. L. Pearce et al.   SCIENCE

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Intraperitoneal therapy for peritoneal cancer

(2010) Ze Lu et al.   Future Oncology

Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines

(2008) D. Buglio et al.   BLOOD